Tantti
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Tantti - overview
Established
2014
Location
Taoyuan, -, Taiwan - China
Primary Industry
Materials
About
Based in China, Tantti is a materials company specializing in the development of advanced products for various industries, particularly in biomedical applications and materials science. Tantti, founded in 2014, is headquartered in Taoyuan, Taiwan. The company focuses on innovative materials and has completed 2 deals to date. Its latest funding round was a PIPE on July 29, 2024, where it raised TWD 225.
000 mn from investors including Harbinger Venture Capital and Mega International Commercial Bank. The entire amount raised to date is TWD 225. 000 mn. Joe Yang serves as the CEO.
Tantti specializes in innovative materials, offering advanced products designed for various industries. Their core offerings include DuloCore® Ⅱ resin, UniTantrix® Microcarriers, and Tantti® SpherTantrix, which are utilized in biomedical applications and materials science. DuloCore® Ⅱ resin is engineered for high-performance applications, while UniTantrix® Microcarriers facilitate efficient cell growth in biotechnology. Tantti® SpherTantrix serves as a versatile platform for drug delivery and regenerative medicine.
The company targets markets in North America, Europe, and Asia, catering to clients from research institutions to large-scale pharmaceutical companies. Tantti's revenue model focuses on direct B2B transactions, primarily with healthcare and biotech firms. The company engages in bulk orders of products like DuloCore® Ⅱ resin and UniTantrix® Microcarriers, essential for biomedical device production and research applications. Transactions are negotiated on a contract basis, allowing for customized pricing structures to meet clients' needs.
This approach fosters long-term relationships with customers, supported by a commitment to quality and innovation. The recent PIPE funding of TWD 225. 000 mn is set to enhance Tantti's product offerings and market reach. In July 2024, Repligen Corporation agreed to acquire Tantti, which will enhance their portfolio in the modality sector.
The acquisition signifies a strategic move for both companies, aiming for expanded capabilities in the biomedical field.
Current Investors
Mega International Commercial Bank, Harbinger Venture Capital, National Development Fund of the Executive Yuan
Primary Industry
Materials
Sub Industries
Biomaterials, Advanced Materials, Nanomaterials, Materials
Website
www.tantti.com
Verticals
Manufacturing
Total Amount Raised
Subscriber access only
Tantti - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Trade Sale | Completed | Tantti | - | ||||||||
| PIPE | Completed | Tantti | - |
Displaying 1 - 2 of 2
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.